10x Genomics, Inc. (NASDAQ:TXG) Q4 2025 Earnings Call Transcript
Operator: Thank you for standing by. My name is Carly, and I will be your conference operator today. At this time, I would like to welcome everyone to the 10x Genomics, Inc.
10X Genomics Inc. (TXG)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bayforest Capital Theodoros Tsagaris | 542 | $11,507 | -97% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.14 | 40,000 | $445,572.00 | 61,691 | 2025-02-21 | Filing | |
| $40.49 | 158 | $6,396.71 | 60,046 | 2022-05-13 | Filing | |
| $40.49 | 158 | $6,396.71 | 97,523 | 2022-05-13 | Filing | |
| $39.00 | 300,000 | $11,700,000.00 | 300,000 | 2019-09-16 | Filing | |
| $39.00 | 300,000 | $11,700,000.00 | 300,000 | 2019-09-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $24.56 | 5,000 | $122,784.00 | 1,167,273 | 2026-04-14 | Filing | |
| $19.52 | 5,000 | $97,611.50 | 1,172,273 | 2026-03-24 | Filing | |
| $19.13 | 10,000 | $191,297.00 | 1,177,273 | 2026-03-23 | Filing | |
| $23.18 | 1,860 | $43,111.27 | 1,203,667 | 2026-03-02 | Filing | |
| $22.67 | 14,292 | $323,985.35 | 1,205,527 | 2026-03-02 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 152,187 | $3,398,336 | 0.01% | |
| 2. | 77,293 | $1,640,930 | 0.23% | |
| 3. | 44,471 | $944,119 | 0.09% | |
| 4. | 35,171 | $746,680 | 0.01% | |
| 5. | 16,366 | $413,078 | 0.01% |
News See All
Barclays Turns More Bullish on 10x Genomics, Inc. (TXG) Despite Uneven Research Spending
On December 15, 2025, Barclays analyst Luke Sergott raised the price target for TXG from $17 to $22 while maintaining an Overweight rating, reflecting confidence in the company’s positioning in life...
7 Most Promising Gene Editing Stocks According to Analysts
Gene editing has rapidly evolved into a transformative class of technologies that allow scientists to precisely insert, delete, or modify DNA within living cells.
10x Genomics Expands Flex Lineup with High-Throughput Single-Cell Assay Launch
On October 29, 2025, 10x Genomics announced the launch of its next-generation Chromium Flex assay, designed to help researchers dramatically scale up single-cell experiments.
10 Best Digital Health Stocks to Buy Now
Digital health’s 2025 shape is pretty clear: money is flowing again, AI is getting absorbed into real workflows, and policy is quietly forcing the pipes to talk to each other.
10x Genomics (TXG) Soars to New Record High on Lower Net Loss, Revenue Beat
Revenues, on the other hand, declined by 1.7 percent to $149 million from $151.6 million in the same comparable period, primarily due to a decrease in instrument revenue.
10x Genomics, Inc. (NASDAQ:TXG) Q3 2025 Earnings Call Transcript
Operator: Thank you for standing by. Welcome to the 10X Genomics' Third Quarter 2025 Earnings Conference Call.
10x Genomics, Inc. (NASDAQ:TXG) Q2 2025 Earnings Call Transcript
Operator: Hello, and thank you for standing by. My name is Tiffany, and I will be your conference operator today.
10x Genomics Settles Patent Dispute With Bruker
10x Genomics, Inc. (NASDAQ:TXG) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds.
11 Best Genomics Stocks to Buy According to Hedge Funds
Genomics is the study of genes and how they operate.
Hedge Fund Resource Center